Nature Reviews Cancer 5, 142-149 (February 2005) | doi:10.1038/nrc1550

OpinionBias as a threat to the validity of cancer molecular-marker research

David F. Ransohoff1  About the author


Claims that molecular markers can accurately diagnose cancer have recently been disputed; some prominent results have not been reproduced and bias has been proposed to explain the original observations. As new '-omics' fields are explored to assess molecular markers for cancer, bias will increasingly be recognized as the most important 'threat to validity' that must be addressed in the design, conduct and interpretation of such research.

Author affiliations

  1. David F. Ransohoff is in the Departments of Medicine and Epidemiology, University of North Carolina at Chapel Hill, CB# 7080, Bioinformatics Building, 4103 Chapel Hill, North Carolina 27599–7080, USA and at the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892–7354, USA.


These links to content published by NPG are automatically generated.


Metabolomic study of cisplatin-induced nephrotoxicity

Kidney International Original Article

Surrogate Endpoints for the Treatment of Venous Leg Ulcers

Journal of Investigative Dermatology Original Article